Feb. 20, 2026Shanghai Fudan Zhangjiang Biopharmaceutical synthesizes new compounds for cancerShanghai Fudan Zhangjiang Biopharmaceutical Co. Ltd. has discovered anthracycline compounds potentially useful for the treatment of cancer.
Feb. 20, 2026Beijing Konruns Pharmaceutical discovers TACC inhibitorsBeijing Konruns Pharmaceutical Co. Ltd. has patented new transforming acidic coiled-coil-containing protein (TACC) inhibitors described as potentially useful for the treatment of cancer.
Feb. 20, 2026NRF2 inhibitors reported in Genfleet Therapeutics patentGenfleet Therapeutics (Shanghai) Co. Ltd. has identified new acryloyl compounds acting as nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2) inhibitors.
